DIAMYD ANNOUNCES COMPLETION OF TYPE 1 DIABETES VACCINE TRIAL WITH LONG TERM EFFICACY DEMONSTRATED AT 30 MONTHS

DIAMYD ANNOUNCES COMPLETION OF TYPE 1 DIABETES VACCINE TRIAL WITH LONG TERM
EFFICACY DEMONSTRATED AT 30 MONTHS

Press Release, Stockholm, Sweden, January 21, 2008 - Diamyd Medical AB
(www.omxgroup.com, ticker: DIAM B; www.otcqx.com, ticker DMYDY)

Diamyd Medical announces today that its novel diabetes vaccine Diamyd®, has
demonstrated statistically significant long-term efficacy in preservation of
beta cell function, i.e. endogenous insulin producing capacity, in patients with
type 1 diabetes.

The results were reported on Saturday, January 19, at the Karl-Stolte Symposium
in Hannover, Germany, by Professor Johnny Ludvigsson, University of Linkoping,
Sweden, the Principal Investigator of the study. The 30 month results comprise
the final timepoint for the now-completed Diamyd® study. Positive results have
previously been reported after 15 and 21 months.

As reported by professor Ludvigsson, the Phase IIb study with the Diamyd®
therapeutic diabetes vaccine met its primary endpoint regarding preservation of
beta cell function as measured by C-peptide, a marker for the body's natural
insulin production. As previously reported, the clear positive effect of Diamyd®
on preservation of beta cell function is also accompanied by a significant and
specific immune response, an additional important factor in evaluating the
effectiveness of the therapy since it is believed Diamyd® acts by modifying the
patient's immune system.

The Diamyd® study, which was conducted at 8 clinical sites in Sweden, included
70 patients aged 10-18 who had been diagnosed with type 1 diabetes within 18
months. 35 patients received two single injections of Diamyd® and 35 patients
received placebo. The newly-presented data showed that 30 months after the first
injection, the Diamyd®-treated group showed statistically significant better
preservation of insulin secretion, both in fasting state and after meal
stimulation, compared to placebo. This indicates that Diamyd® has successfully
protected the beta cell function. The protective effect remains most pronounced
in patients treated early after disease diagnosis.

“Saving a patient's beta cell function is of great clinical value as it makes it
easier for the patient to handle the disease and leads to an improved quality of
life”, says Professor Ludvigsson. ”It has also been shown that even a small
maintained beta cell function in progressed type 1 diabetes can reduce acute and
late complications”.

“These results are extremely positive”, says Elisabeth Lindner, CEO and
President for Diamyd Medical. ”These data demonstrate that the Diamyd® treatment
provides a long term, lasting benefit for beta cell function in type 1 diabetes
patients. Additionally, the treatment is very easy to administer and appears
safe, with no treatment-related serious adverse events seen in any trial to
date. The plan is now to commence Phase III studies in order to confirm the
positive results and then to apply for registration of the product”.

For further information, please contact:
Stockholm office
Elisabeth Lindner
CEO and President 
+46 8 661 0026
investor.relations@diamyd.com

Stockholm office
Anders Essen-Möller
Chairman
+46 8 661 0026
anders.essen-moller@diamyd.com

Pittsburgh office
Michael Christini
President
+1 412 770 1310
michael.christini@diamyd.com

Diamyd Medical AB (publ). Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46
8 661 00 26, fax: +46 8 661 63 68 or E-mail: info@diamyd.com. VATno:
SE556530-142001.

About Diamyd Medical
Diamyd Medical is a life science company developing treatments for diabetes and
its complications. The company's furthest developed project is the GAD-based
drug Diamyd® for autoimmune diabetes for which Phase III studies are planned.
Diamyd® has demonstrated significant and positive results in Phase II clinical
trials in Sweden.

GAD65, a major autoantigen in autoimmune diabetes, is the active substance in
Diamyd. GAD65 is also an enzyme that converts the excitatory neurotransmitter
glutamate to the inhibitory transmitter GABA. In this context, GAD may have an
important role not only in diabetes but also in several central nervous
system-related diseases. Diamyd Medical has an exclusive worldwide license from
the University of California at Los Angeles regarding the therapeutic use of the
GAD65 gene.

Diamyd Medical has sublicensed its UCLA GAD Composition of Matter license to
Neurologix, Inc. in Fort Lee, New Jersey for treatment of Parkinson's disease
with an AAV-vector.

Other projects comprise drug development within therapeutic gene transfer using
the exclusively licensed and patent protected Nerve Targeting Drug Delivery
System (NTDDS). The company's lead NTDDS projects include using enkephalin and
GAD for chronic pain, for which a phase I clinical study is planned.

Diamyd Medical has offices in Stockholm, Sweden and Pittsburgh, PA. The Diamyd
Medical share is quoted on the Stockholm Nordic Exchange in Sweden (NOMX ticker:
DIAM B) and on the OTCQX-list in the United States (ticker: DMYDY) administered
by the Pink Sheets and the Bank of New York (PAL). Further information is
available at www.diamyd.com.

Disclaimer: This document contains certain "statements" relating to present
understandings, future events and future performance, including statements
relating to the progress, timing and completion of our research, development and
clinical trials; our ability to market, commercialize and achieve market
acceptance for product candidates; and our current and future strategic partner
relationships. These statements can be affected by inaccurate assumptions or by
known or unknown risks and uncertainties. Diamyd Medical undertakes no
obligation to publicly update such statements, whether because of new
information, future events or otherwise, nor does Diamyd Medical give any
guarantees that the statements, given or implied, are correct. This document is
a translation from the Swedish original. No guarantees are made that the
translation is free from errors.